Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L).

"All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf: YO reported receiving honoraria from Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, and Novartis, Japan. YK reported receiving research grants from Takeda Pharmaceutical Company, Ltd. and Chugai Pharmaceutical Co., Ltd., and honoraria from Takeda Pharmaceutical Company, Ltd., and Chugai Pharmaceutical Co., Ltd. TS reported receiving research grants from Chugai Pharmaceutical Co., Ltd. and Novartis Pharma K.K., and honoraria from Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Takeda Pharmaceutical Company Ltd. KO reported receiving honoraria from Chugai Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Company Ltd. EI reported receiving research grants from Takeda Pharmaceutical Company Ltd. and Pfizer Japan Inc., and honoraria from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Ltd., Novartis Pharma K.K., and Pfizer Japan Inc. SM reported receiving grants from Chugai Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Company Ltd., and personal fees from Pfizer Japan Inc., Chugai Pharmaceutical, and Takeda Pharmaceutical Company Ltd. NY reported receiving grants from Chugai Pharmaceutical, Novartis Pharma K.K., and Takeda Pharmaceutical Company Ltd., and honoraria from Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc., and Takeda Pharmaceutical Company Ltd."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Takeda Pharmaceutical Company Limited."

"Trial registration: UMIN000042439."